Phase 2
Completed N=64
Study Evaluating the Effects of Toradol and Lyrica for Pain Control After Donor Nephrectomy
Pain, Postoperative
Source: ClinicalTrials.gov NCT03669081 ↗
Enrolled (actual)
64
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcomePrimary: Cumulative Narcotic Use — 27; 45 mg — p=0.006
Summary
The investigators will assess how the use of toradol and pregabalin affects return to bowel function and see if there is a difference in length of hospital stay. Narcotic use can affect bowel function so the investigators hypothesize that use of Toradol will decrease delayed bowel function and aid in a patients discharge and reduction of hospital stay.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cumulative Narcotic Use |
27; 45 | 0.006 sig |
| PRIMARY Length of Hospital Stay |
51.5; 57.3 | 0.029 sig |
| SECONDARY Serum Creatinine Levels at One Year Post-operatively |
0.6; 0.7 | <0.0001 sig |
| SECONDARY Bleeding Risk |
6.3; 4.3 | 0.002 sig |
| SECONDARY Number of Patients With Urinary Retention |
1; 0 | >0.99 |
| SECONDARY 30 Day Mortality |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Patients anticipating donating a kidney in a live kidney donor transplant.
Exclusion Criteria
- Patients not receiving a donor nephrectomy
- Pregnant, lactating, or nursing mothers
- Medical allergies or history that would otherwise be contraindicated for of a non-steroidal anti-inflammatory drug.
Data sourced from ClinicalTrials.gov (NCT03669081). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.